[144] Enact Holdings, Inc. SEC Filing

Rhea-AI Filing Summary

Enact Holdings, Inc. (ACT) filed a Form 144 disclosing a proposed sale of 86,406 common shares through J.P. Morgan Securities LLC on 08/27/2025 on the NYSE. The filing reports an aggregate market value of $749,140 for the proposed sale and shows 410,433,925 shares outstanding.

The shares were acquired as compensation: 59,080 shares on 03/25/2024 and 27,326 shares on 03/01/2024. The filer reports no securities sold in the past three months and includes the standard representation that they are not aware of any undisclosed material adverse information about the issuer.

Insights

Securities Analyst

TL;DR: Routine insider sale notice: 86,406 shares proposed for sale, representing a very small fraction of outstanding stock.

The Form 144 is a standard regulatory notice required when insiders propose to sell restricted or control securities under Rule 144. The proposed block of 86,406 shares has an aggregate market value of $749,140 against 410.4 million shares outstanding, indicating the sale is immaterial to the company’s market capitalization. The shares were received as compensation in March 2024, and no sales were reported in the prior three months. From a liquidity and dilution perspective, this filing is unlikely to move the stock absent other disclosures.

Corporate Governance Expert

TL;DR: Compliance-focused disclosure; contains standard attestations and no red flags about undisclosed material information.

The filing includes the required certification that the seller is not aware of undisclosed material adverse information and references potential Rule 10b5-1 trading plans. Acquisition details show compensation-based grants in March 2024. There are no indications of accelerated insider selling or recent related-party transactions in the three-month window. Governance implications are routine: disclosure meets Rule 144 formality but does not suggest governance concerns on its face.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	J.P. Morgan Securities LLC 390 Madison Avenue 6th Floor New York NY 10017	86406	749140	410433925	08/27/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/25/2024	Compensation	Issuer			59080	03/25/2024	Compensation
Common	03/01/2024	Compensation	Issuer			27326	03/01/2024	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Enact Holdings' (ACT) Form 144 disclose?

The filing discloses a proposed sale of 86,406 common shares via J.P. Morgan on 08/27/2025, with aggregate value $749,140 and 410,433,925 shares outstanding.

When were the shares to be sold originally acquired?

All shares were acquired as compensation: 59,080 on 03/25/2024 and 27,326 on 03/01/2024.

Did the filer report any sales of issuer securities in the past three months?

No. The filing states "Nothing to Report" for securities sold during the past three months.

Which broker is handling the proposed sale?

The proposed sale lists J.P. Morgan Securities LLC (390 Madison Avenue, New York) as the broker.

Does the Form 144 indicate undisclosed material information about Enact Holdings?

No. The signer represents they do not know of any material adverse information about the issuer that has not been publicly disclosed.